High Content Screening - Emerging importance of novel reagents/probes and pathway analysis By Dr John Comley The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in applying HCS… Read More
Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in silico technique, in… Read More
The Impact of RNAi on Drug Discovery By Dr Christopher P. Miller RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice for target… Read More
The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines By Professor Jan Tornell The pharmaceutical industry is faced with the challenge to deliver truly novel medicines to a market under financial pressure when pharmaceutical R&D becomes increasingly difficult and complex. This review will mainly focus on… Read More
Experimental Medicine - Developing biomarkers in early discovery to bridge preclinical and clinical development By Dr Robert Dix In today's pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing), resulting in… Read More
Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved productivity and limited drug pipeline growth is… Read More
Leveraging the ion channel platform for lead generation in atrial fibrillation By Professor Andreas Busch Competition in the pharmaceutical industry requires a reduction in research and development project cycle times and, accordingly, an increase in productivity and efficiency. Pharmaceutical companies also are faced with the challenge of translating massive amounts… Read More
GENE EXPRESSION as a toxicological screening tool By Dr Bruce Seligmann The use of microarray data in drug development and requirements for FDA audit and approval. Toxicological safety testing of compounds has not yet advanced to the point where measurement of gene expression is being incorporated in the internal decision… Read More
The impact of early ADME profiling on drug discovery and development strategy By Dr Jianling Wang and Dr Laszlo Urban The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to a new strategy… Read More
Functional screening of viral siRNA libraries in human primary cells By Dr Kara Bortone, Dr Frits Michiels, Dr Nick Vandeghinste, Dr Peter Tomme and Dr Helmuth van Es One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets in underserved… Read More
Novel concepts and therapeutic options for the treatment of schizophrenia By Dr Karoly Nikolich and Dr Roman Urfer Schizophrenia affects a large number of individuals irrespective of social status and education. Current treatments of schizophrenia represent the second largest central nervous system (CNS) pharmaceutical market, exceeding $12 billion per year. Read More
Metabonomics - A generic platform for the investigation of drug toxicity, altered gene function and disease processes By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry's biggest problems attrition. This article discusses the scope and uses of metabonomics… Read More
By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in place a powerful system… Read More
Share Share Tweet Email Tools for Structural Genomics - Accelerating the structure pipeline Tools for Structural Genomics - Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr Shankari Mylvaganam The international structural genomics effort has resulted in a number of technological… Read More
Functional cell-based high throughput drug screening By Professor Daniel T. Chiu and Professor Owe Orwar Cell-based assays are poised to assume an increasingly important role in drug screening and discovery. It is becoming apparent that simple binding assays and in vitro experiments are grossly insufficient for extrapolating the efficacy and… Read More
Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression or expression… Read More